Equipment and Processing Report
igital tracking of overall equipment effectiveness can improve efficiency.
With the November 2017 deadline for the Drug Supply Chain Security Act (DSCSA) looming, US pharmaceutical manufacturers, contract manufacturing organizations, and contract packaging organizations are getting their serialization solutions ready and validated. Few, however, are as concerned with what happens next. While widespread track-and-trace adoption will help mitigate many longstanding problems-counterfeiting, supply chain security, pinpointing recalls-it will create issues well beyond the immediate hassles of infrastructure investment, implementation, and validation. Most prominent is loss in production line efficiency. As manufacturers continue to outfit and upgrade packaging machinery to comply with regulations, the extra steps in serialization (and aggregation) will bring an unwelcome 5–10% reduction in overall equipment effectiveness (OEE), as experienced by early adopter countries such as Turkey. Some companies have seen decreases of 20–30%.
The good news is that with serialization incorporation, any process causing an initial slowdown can produce data that, when properly interpreted, can reveal a roadmap to restoring OEE to pre-track and trace levels, or even higher. Data generated by serialization compliance can be parlayed into guideposts for improving production practices. The metrics are there for the mining, allowing manufacturers to track and trace their operations along with their pharmaceutical products with exceptional granularity.
Serialization implementation and the data mining it affords are the first vital steps toward transforming pharma production facilities into digital factories whose foundations are built on web-enabled and data-driven technologies. Its advantages touch every aspect of manufacturing, including enterprise-wide resource allocation, asset tagging, and real-time inventory and personnel tracking.
Digital factory transformation
Tomorrow’s digital factories can use a three-tiered digital transformation process to successfully deliver the promise of smart manufacturing, or Industry 4.0. The race is on for manufacturers to optimize production practices by navigating from data to dashboards to decisions. In doing so, they will apply mined information toward comprehensive yet digestible operational feedback that, in turn, leads to logical adjustments for improved production practices. The three “D”s of this process are described as follows:
Scheduling and beyond
Replacing manual or paper-based tracking with a digital tracking system improves operational visibility and allows identification of procedure-driven activities that show significant variability in duration so that managers can identify areas for improvement. Such systems can also help allocate personnel more efficiently, in real time. More fundamental performance improvement can use digital tracking of shop floor activities to create a more robust scheduling process. Digital tracking can thus improve management of operations.
About the Author
Evren Ozkaya, PhD, is founder and CEO of Supply Chain Wizard, LLC, www.supplychainwizard.com.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.